Skip to main content
. 2021 Oct 19;12:746594. doi: 10.3389/fphar.2021.746594

FIGURE 1.

FIGURE 1

Schematic representation of the PBPK-DO model for saxagliptin in humans. The PBPK-DO model includes the gut lumen, enterocytes, the portal vein, the liver, blood (arterial supply and venous return), the lung, and other eliminating tissues (kidney) and non-eliminating tissues (11 compartments). The CYP3A metabolism enzyme was set into enterocytes and liver compartments. DPP-4 was assumed to only reside in the venous return compartment.